DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Biotech team weigh up European orphan drug opportunity.

The Challenge

Our client was a US-based clinical stage biotech company developing a reformulation of a well-established orphan drug targeting a range of indications in neuro-endocrinology.

Client leadership requested DRG to validate key assumptions on the revenue forecast of the drug in its lead indication and provide guidance on the go-to-market model and associated costs in order to inform a go/no go decision on launch of the drug in Europe.

The client needed to understand:

  • The size of the addressable patient population given epidemiology and the evolution of treatment landscape
  • Pricing and access expectations, and potential price/access trade-offs
  • Uptake and peak preference share given the current and future competitive landscape
  • Medical, access and commercial resources required for a successful launch